Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3% diquafosol for allergic conjunctivitis-related dry eye
ChiCTR2000034413Phase 4Not yet recruiting
- Sponsor
- Ophthalmic Center of the Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of diquafosol in dry eye syndrome (DED) and allergic conjunctivitis (AC), sponsored by Ophthalmic Center of the Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Change in tear film breakup time at 4 weeks. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
diquafosol
03
Conditions
dry eye syndrome (DED)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on ChiCTR2000034413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034413.